Atlas Trials

CABozantinib in Non-Small Cell Lung Cancer (NSCLC) Patients With MET Deregulation

Clinical trial NCT03911193 · UNKNOWN

Trial details

NCT number
NCT03911193
Sponsor
Fondazione Ricerca Traslazionale
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Non-Small Cell Lung Cancer
Start date
2018-09-21
Primary completion
2020-09-01
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.